Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of …
Biotechnology
BE, Mechelen [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -401.81 | -207.59 | -41.37 | |
| Graham Fair Price | -22.86 | 36.79 | 47.69 | |
| PEG | -76.91 | -0.02 | < 0.005 | |
| Price/Book | -23.19 | 0.55 | 0.72 | |
| Price/Cash Flow | 52.01 | -12.95 | -26.99 | |
| Prices/Earnings | 38.91 | 4.45 | 3.20 | |
| Price/Sales | 166.43 | 25.73 | -9.66 | |
| Price/FCF | 52.01 | -12.95 | -26.99 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -31.67 | 0.96 | 1.40 | |
| Operating Margin | 105.48 | -0.68 | 0.33 | |
| ROA | -42.79 | 0.02 | 0.04 | |
| ROE | 0.06 | 0.03 | -44.71 | |
| ROIC | -0.02 | -0.02 | 35.18 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.17 | -0.32 | 47.55 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -1.29 | 0.39 | -70.09 | |
| EPS QOQ | -3.26 | 2.56 | -21.48 | |
| FCF QOQ | 0.39 | -0.66 | 70.02 | |
| Revenue QOQ | -2.74 | 1.30 | -52.65 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 78.86 | 2845.46 | 3508.14 | |
| Days Sales Outstanding (DSO) | -28.26 | 132.69 | 369.61 | |
| Inventory Turnover | 1.14 | 0.03 | -97.23 | |
| Debt/Capitalization | < 0.005 | < 0.005 | -19.67 | |
| Quick Ratio | 8.76 | 9.55 | 9.04 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 42.35 | 43.93 | 3.74 | |
| Cash | 55.82 | 53.99 | -3.27 | |
| Capex | -0.12 | -0.10 | 21.37 | |
| Free Cash Flow | -1.13 | -1.88 | -66.03 | |
| Revenue | -3.17 | 0.95 | -70.09 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad